Discounted Cash Flow (DCF) Analysis Unlevered

Onconova Therapeutics Inc. Warrants (ONTXW)

$0.0671

-0.02 (-25.44%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.0671 | undervalue

Operating Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 5.550.791.232.180.230.210.190.170.150.13
Revenue (%)
EBITDA -19.56-23.99-20.64-21.48-25.14-7.02-6.29-5.64-5.06-4.53
EBITDA (%)
EBIT -19.65-24.08-20.70-21.49-25.15-7.03-6.30-5.65-5.06-4.54
EBIT (%)
Depreciation 0.100.090.050.010.010.010.010.010.010.01
Depreciation (%)

Balance Sheet Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash 21.404.0216.9722.7319.034.794.293.853.453.09
Total Cash (%)
Account Receivables 0.030.060.040.100.040.010.010.010.010.01
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 5.326.194.044.274.831.451.301.161.040.94
Accounts Payable (%)
Capital Expenditure ----0.06-0.01-0.01-0.01-0.01-0.01-0.01
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.0,671
Beta 4.068
Diluted Shares Outstanding -
Cost of Debt
Tax Rate -0.02
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 23.006
Total Debt -
Total Equity -
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 5.550.791.232.180.230.210.190.170.150.13
EBITDA -19.56-23.99-20.64-21.48-25.14-7.02-6.29-5.64-5.06-4.53
EBIT -19.65-24.08-20.70-21.49-25.15-7.03-6.30-5.65-5.06-4.54
Tax Rate -0.07%-0.05%-0.19%-0.05%-0.02%-0.08%-0.08%-0.08%-0.08%-0.08%
EBIAT -19.67-24.09-20.74-21.50-25.16-7.03-6.31-5.65-5.07-4.54
Depreciation 0.100.090.050.010.010.010.010.010.010.01
Accounts Receivable --0.030.02-0.060.060.020000
Inventories ----------
Accounts Payable -0.86-2.150.230.56-3.38-0.15-0.13-0.12-0.11
Capital Expenditure ----0.06-0.01-0.01-0.01-0.01-0.01-0.01
UFCF -19.57-23.17-22.80-21.38-24.54-10.39-6.45-5.79-5.19-4.65
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -4.74
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -19.02
Equity Value -
Shares Outstanding -
Equity Value Per Share -